Connect with us
https://tickernews.co/wp-content/uploads/2023/10/AmEx-Thought-Leaders.jpg

Leaders

Glioblastoma awareness day

Published

on

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is an oncology-focused drug development company.

Their lead program is paxalisib, which is being developed to treat glioblastoma (GBM), the most common and aggressive form of primary brain cancer in adults. There are few treatment options for sufferers of GBM and around 65% of sufferers do not respond to currently available treatments. The condition affects around 133,000 people globally per annum and the potential addressable market is worth more than US$1 billion.

Kazia’s drug paxalisib, commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Eight additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data for EVT801 has shown it to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno- oncology agents.

A phase I study is expected to begin in CY2021. Competitive Advantages: – Lead program, paxalisib, sourced from the world’s most successful cancer drug developer, Genentech – Experienced team with extensive backgrounds in big pharma and biotech – Around 65% of GBM sufferers do not respond to current treatments – Multiple shots on goal with collaborations progressing in other cancers; largely funded by participating hospitals.

For more information, head to their website.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Leaders

Essential daily protein needs for better health

Published

on

Protein is a fundamental macronutrient essential for various bodily functions, including muscle repair, enzyme production, and immune system support.

Daily protein requirements can vary significantly based on factors such as activity levels, age, and gender.

To help unpack this topic, Kate Save from BeFitFood joins to share her key insights. #featured

Continue Reading

Leaders

What makes a successful swimwear brand?

Published

on

Meet the entrepreneur shaking up the swimwear space with versatile designs.

 

Take Your Shot is an insightful talk show dedicated to exploring the journeys of entrepreneurs and innovators within their respective fields. With a focus on both triumphs and tribulations, the program delves into the stories of individuals navigating the complexities of business, offering valuable insights into the pursuit of success.

Hosted by Samuel Levi, CEO & Founder of LuxeSticks.

In this episode, Samuel is joined by Christina Podolyan, Founder of Kahlu Swim.

#take your shot

Continue Reading

Leaders

Entrepreneur shifts diet culture

Published

on

What does it take to build a brand with cut through?

Take Your Shot is an insightful talk show dedicated to exploring the journeys of entrepreneurs and innovators within their respective fields. With a focus on both triumphs and tribulations, the program delves into the stories of individuals navigating the complexities of business, offering valuable insights into the pursuit of success.

Hosted by Samuel Levi, CEO & Founder of LuxeSticks.

In this episode, Samuel is joined by Jess Davis, Founder of Mr. Potato.

Continue Reading

Trending Now